The use of moist oxygen anion from PUVICO3 technology for air purification and supportive treatment of COVID-19 infection: Synergistic potential and possibilities Available to Purchase

From late 2019 to March 2020, a new type of virulent coronavirus called SARS-CoV-2 came into the world. It spread as an extensive and massive pandemic outbreak in various parts of the world, both developed and developing countries. This pandemic has attacked many countries globally, especially the second wave of attacks of the Delta variant during the period March to June 2021, which has increased the number of infection victims, both confirmed and dead. In addition, the second wave phenomenon also creates worrying vulnerabilities in health facilities in various parts of the world, especially in India, Indonesia and even the USA and South America countries with all its impacts on their lives. Massive efforts worldwide to end the pandemic, including preventing the spread of SARS-CoV-2, vaccinations, antiviral drugs, and even symptom relief, are still underway. However, there is no effective treatment to save severe patients, both lung infection and hyperinflammatory effects. From the various genetic and characteristic analyzes of SARS-CoV-2 that have been carried out, it was found that the spike protein (S) increases the positive charge around the viral receptor or the ACE2 enzyme, even until it infiltrates the lungs. Empirically, this study develops a hypothesis that the PUVICO3 technology studied so far can provide moist oxygen anion (O2−[H2O]n) in a low ozone environment (< 0.5 ppm). Exposure to UV-C irradiation of±80 W/m2 can help neutralize viral spike protein (S) in the respiratory tract until it reaches the lungs. It changes the lung environment to a neutral or better condition and can further facilitate increased oxygen tension in the blood. These physical changes can effectively reduce viral loads, and further help patients recover from infections more quickly.